Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Adv Drug Deliv Rev. 2015 Oct 27;97:156–173. doi: 10.1016/j.addr.2015.10.012

Table 2.

Perlecan’s processed forms in biological tissues and fluids.

Tissue/Fluid Condition Endorepellin and its fragments Biomarker for References
Murine aged gastrocnemius muscle extracts Sarcopenia LG1/2 Age-related loss of skeletal muscle mass and function [285]
Secretome of mast cells Inflammation Endorepellin and shorter forms Inflammation [160]
Secretome of endothelial cells Apoptotic endothelial cells LG3 and other endorepellin’s fragments Fibrosis [194]; [152, 283]; [299]
Secretome of pancreatic and colon carcinoma cells Colon carinomas and pancreatic cancer LG3 and other endorepellin’s fragments High turnover rate of cancer cells [193]; [287]
Secretome of neurons and neurovasculature cells Brain infarcts LG3 Oxygen and glucose deprivation in neuronal cells [281, 282]
Growth plate of fetal cartilage (upper zone) Blood vessel invasion within cartilage Endorepellin Fetal ischemia and vascular injury [196]
Amniotic fluid Premature rupture of fetal membranes LG3 Fetal ischemia and vascular injury [277]; [278]
Amniotic fluid Mothers carrying Down Syndrome fetuses LG3 Abnormal fetal development and vascular injury [279]
Urine End-stage renal disease LG3 Vascular injury [284]
Urine Chronic allograft nephropathy LG3 Immune-mediated vascular injury [197]
Urine Children with sleep apnea LG3 Brain ischemia [280]
Blood Patients with refractory cytopenia with multilineage dysplasia LG3 Refractory cytopenia with multilineage dysplasia [286]
Blood Normal subjects and breast cancer patients LG3 Breast cancer [183]